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Abstract The search of reprolysin inhibitors offers the possi-
bility of intervention against both matrixins and ADAMs. Here 
we report the crystal structure of the complex between 
adamalysin II, a member of the reprolysin family, and a 
phosphonate inhibitor modeled on an endogenous venom tripep-
tide. The inhibitor occupies the primed region of the cleavage site 
adopting a retro-binding mode. The phosphonate group ligates 
the zinc ion in an asymmetric bidentate mode and the adjacent 
Trp indole system partly fills the primary specificity subsite Si'. 
An adamalysin-based model of tumor necrosis factor-a-convert-
ing enzyme (TACE) reveals a smaller Si' pocket for this enzyme. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Reprolysins, also known as adamalysins [1], are snake ven-
om zinc-endopeptidases that hydrolyze basement membrane 
proteins involved in the adhesion among capillary endothelial 
cells, inducing extensive haemorrhages in the bitten preys [2]. 
Matrixins (matrix metalloproteinases, MMPs) are zinc-de-
pendent enzymes that degrade the major components of the 
extracellular matrix. Although they play an important phys-
iological role in tissue remodeling and repair, their aberrant 
regulation has been implicated in pathologies such as tumor 
metastasis, rheumatoid arthritis and multiple sclerosis [3]. 
These two classes of proteinases, together with serralysins 
and astacins, have been grouped into the superfamily of 'met-
zincins' [1], because of similar zinc-dependent catalytic do-
mains. The similarities of reprolysins and MMPs [4], as well 
as their high degree of tertiary structure conservation at the 
active site [5], suggest that the binding of substrates and in-
hibitors may be similar. Depending on the number of do-
mains, the multimodular reprolysins have been subdivided in 
four classes: P-I, when only a zinc-dependent proteolytic do-
main is contained, P-II, P-III and P-IV, when a disintegrin, a 
cysteine-rich and a lectin domain, respectively are also in-
cluded [6]. Interestingly, also animal tissues produce a large 
number of multi-domain proteins, generally called ADAMs 
[7], that contain the same domains of P-IV reprolysins, and 
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have been therefore included in this family of enzymes [8]. 
ADAMs are present in a wide range of organisms and mam-
malian tissues and appear to be transmembrane proteins 
whose physiological role has not yet been clearly understood, 
even though some of them seem involved in fertilization proc-
esses [9], neurogenesis [10] or degradation of bovine myelin 
basic protein [11]. The tumor necrosis factor-a (TNF-a) is a 
cytokine involved in many inflammatory diseases [12] and is 
released into blood circulation by TNF-a-converting enzyme 
(TACE). According to a recent finding TACE belongs to the 
group of ADAM 10 [13]. 
In this context, the search of reprolysin inhibitors offers the 
possibility of intervention against both matrixins and 
ADAMs. Moreover, the finding that in crotalid and viperid 
snake venoms there are also present large amounts of pyro-
glutamate (Pyr) containing tripeptides (Pyr-Asn-Trp and Pyr-
Glu-Trp), acting as weak and competitive inhibitors of repro-
lysins [14], suggested us to modify these endogenous peptides 
rather than the natural substrates, for obtaining novel types of 
more powerful inhibitors. Tripeptide derivatives such as Pyr-
Leu-Trp-OMe (POL509) and 2-Furoyl-Leu-Trp (POL647) 
have been already tested as possible innovative agents in the 
field of immunological reactions and for reducing damages 
induced by snake venoms and TNF-a. At this regard, 
POL509 showed immunomodulatory effects in rats 'in vivo' 
[15], depending on increased antigen presentation efficiency 
[16]; POL647 inhibited the haemorrhagic activity of Echis 
Pyramidum Laekeyi venom and its isolated haemorrhagin 
[17] and prevented the processing of TNF-a precursor by 
snake venom reprolysins [18]. Further modifications of the 
above peptides, promoting tighter binding to the adamalysin 
II active site, considered as the reprolysin prototype [19], have 
been carried out by our group. Novel compounds, character-
ized by the presence of a phosphonate group and possessing 
broad spectrum inhibitory activities on some zinc-dependent 
proteinases have been synthesized and will be reported in a 
forthcoming paper. In order to reveal the mode of binding of 
these phosphonate inhibitors, here we report the crystal struc-
ture of adamalysin II complexed with an analogue of 
POL647, in which the terminal carboxyl has been replaced 
by the phosphonate group. 
2. Materials and methods 
For preparation of the inhibitor the diastereomeric diethyl esters 
2-Furoyl-Leu-(D,L)Trp(P)(OEt)2 were synthesized and separated by 
silica-gel chromatography. The corresponding phosphonic acids 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)01401-4 
320 M. Cirilli et al.lFEBS Letters 418 (1997) 319-322 
were obtained by hydrolysis. The phosphonic acid deriving from the 
fast-moving (TLC) diethyl ester gave an IC5o = 0.3 uM on adamalysin 
II, a value about ten times smaller than that showed by the other 
diastereomer. The more potent isomer was used for preparation of the 
complex. The configuration at the Trp(P) Ca was determined by the 
present investigation and is reported in Section 3. 
Adamalysin II was purified as previously described [20]. 
Crystals of the complex were obtained by sitting drop vapour dif-
fusion technique. Droplets were made by mixing 6 ul of a 5 mg/ml 
adamalysin II solution in 5 mM CaCl2, 5 mM ZnCl2, 1 mg/ml inhib-
itor, 10 mM Tris, pH 8, with 1.5 ul of a 1.8 M (NH4)2S04 solution, 
pH 5. Droplets were allowed to equilibrate against the same 
(NH4)2S04 buffer as reservoir solution at 4°C. Trigonal, prism shaped 
crystals of maximum dimension 0.5 mm X 0.2 mm X 0.1 mm were ob-
tained and harvested with 2.5 M (NH4)2S04 solution, 5 mM CaCl2, 
5 mM ZnCl2, 2 mM inhibitor, pH 5. 
X-ray intensity data were collected at 4°C on a 180 mm MAR 
image plate area detector (MAR Research, Hamburg) with the Syn-
chrotron Radiation Source at Elettra (Trieste), processed by DENZO 
[21] and CCP4 [22]. Native protein coordinates were taken from the 
PDB (ref HAG) [23]. Refinement was performed by XPLOR [24]. 
Molecular modeling of the inhibitor was made by Chem-X [25], elec-
tron density maps were inspected using O [26] on a Silicon Graphics 
workstation. Data collection and refinement statistics are reported in 
Table 1. The coordinates of the inhibitor complex have been deposited 
with the PDB (ref. 4AIG). 
The inhibitory activity was measured by the fluorescence of the 
cleaved substrate 2-aminobenzoyl-Ala-Gly-Leu-Ala-p-nitrobenzyl-
amide at different inhibitor concentrations. 
3. Results and discussion 
The structure of the complexed enzyme is practically iden-
tical to that of the native enzyme [19]. The root-mean-square 
deviation between the backbone atoms of the inhibited and 
native enzyme is 0.26 A. The largest deviations affect the C a 
atoms of the Pro168-Leu170 segment that is exposed to the 
solvent. The active site is characterized by the strictly con-
served zinc-binding motif HExxHxxGxxH. The 'edge strand' 
Ile108-Ser114 together with the segment His129-Leu135 form the 
'upper rim' of the active site cleft while the segment Pro168-
Leu170 separates the Si' pocket from the bulk solvent. These 
segments furnish groups for the binding of either the substrate 
or the inhibitor. 
The 'omit' electron density map, shown in Fig. 1, clearly fits 
the stereoisomer corresponding to the (R)-Trp(P), therefore 
the inhibitor is the A7-[(furan-2-yl)carbonyl]-(S)-leucyl-(R)-
[l-amino-2(l//-indol-3-yl)ethyl]-phosphonic acid. This map 
also shows that the inhibitor peptide chain occupies the 
primed region of the cleavage site, adopting an almost ex-
tended conformation; the largest deviation from the extended 
form is given by the Leu residue with <p = — 83°, \|f = 133°. 
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Fig. 2. Schematic representation of the interactions formed by the 
phosphonate group in the active site. Dotted and dashed lines repre-
sent zinc coordination and possible H-bonds, respectively. Distances 
in A. 
Two phosphonate oxygens ligate the electrophilic zinc ion 
in an asymmetric bidentate mode (distances are 2.0 and 2.8 A, 
respectively) as shown in Fig. 2, provoking displacement of 
the catalytically essential water molecule that in the uncom-
plexed enzyme is the fourth zinc ligand [19]. Similar asymmet-
ric bidentate binding mode between zinc ion and oxygen 
atoms bound to phosphorous containing inhibitors have 
been found in the crystal structures of complexes of thermo-
lysin [27,28], carboxypeptidase A [29] and astacin [30]. 
The zinc ion adopts a distorted tetrahedral geometry; 
among the coordination angles, the His152 Ne2—Zn—Oi 
(145°) presents the largest deviation. The distorted coordina-
tion allows the approach to the metal of the additional phos-
phonic oxygen Oi (2.8 A) that is also close to both oxygens 
(2.9 and 3.2 A) of the Glu143 side-chain. This residue is sup-
Table 1 
Data collection and refinement statistics 
Crystal system 
Space group 
Cell parameters (A) 
X(A) 
No. collected data 
No. unique reflections 
Completeness (%) (all shells) 
Completeness (%) (last shell) 
-"merge 
Resolution range 
No. reflections used in refinement 
Protein atoms (all active) 
Water molecules 
R-factor 
Mean B factor (A2) - protein 
Mean B factor (A2) - inhibitor 
Mean B factor (A2) - ions 
Mean B factor (A2J) - waters 
R.m.s. deviation (A) - bonds 
R.m.s. deviation (°) - angles 
Trigonal 
P3212 
a = b = 73.5, c = 96.9 
1.0 
53112 
19533 
95.4 (20.0-2.0 A) 
98.3 (2.05-2.00 A) 
0.112 
20.0-2.0 A 
18583 
1607 
191 
0.177 (6.0-2.0 A) 
22.2 
29.7 
16.5 
42.2 
0.007 
0.95 
Fig. 1. Stereo view of the adamalysin II active site and inhibitor 
superimposed on the final 2F0-FC electron density map contoured at 
lo. 
J W = EA£/(I*(M-</(A)>I)/£*£/ ' (*. '") . where I(h,i) is the 
intensity value of the /th measurement of h and (1(h)) is the corre-
sponding mean value of h for all i measurements of h. 
R-factor = £ | F 0-F c | / £ F 0 . 
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Fig. 3. Shape of the Si' pocket partly filled by the Trp side-chain of 
the inhibitor, drawn by GRASP [32]. 
posed to polarize the zinc bound water molecule for the nu-
cleophilic attack to the scissile peptide bond during enzyme 
hydrolysis [31]. 
The inhibitor Trp indole ring, adopting the (g+,t) confor-
mation, occupies the unusually deep primary specificity Si' 
subsite, with an orientation almost parallel to the ring of 
His142 and a distance between the two ring centroids of 
3.4 A. Moreover, the Trp side-chain NEl is anchored to the 
Arg167 CO group by a H-bond. It is interesting to observe that 
the bulky side-chain of Trp has replaced three water molecules 
that are present in the Si' pocket of the native enzyme [19]; 
this suggests that the internal water molecules can be dis-
placed and ejected into bulk solvent. However, the Si' pocket 
is not completely filled by the Trp side-chain and its lower 
part still contains two ordered water molecules interconnected 
by H-bonds with themselves and the surrounding polar 
groups (Cys164 CO, He165 CO, Gly169 CO, Thr171 NH). These 
solvent positions furnish useful indications for the design of 
bulkier groups to insert at Pi ' position of the inhibitor for 
enhancing its binding affinity. We have calculated the volumes 
Table 2 
Structure-based sequence alignment of adamalysin II (ADA) and 
TACE reported around the edge strand segment of the 'upper rim' 
(residues 102-114), the zinc-binding consensus sequence (residues 
130-154) and the Met-turn (residues 165-170) 
ADA . . . N F E G K I I G K A Y T S . 
TACE . . . D F D M G T L G L A Y V G . 
ADA 
TACE 
ADA 
TACE 
S P I N L L V A V T M A H E L G H N L G M E H D G . 
T 1 L T K E A D L V T T H E L G H N F G A E H D P . 
I M E P G 1 . 
V M Y P I A . 
~2.7_^„ P ^ / 
Fig. 4. Scheme of the H-bonds (dashed lines, distances in A) be-
tween the active site and inhibitor polar groups. The letters R and 
S indicate the configurations at the chiral centers of the inhibitor. 
of the adamalysin II Si' pocket (306 A3) and of its portion not 
filled by the inhibitor (189 A3) using the program GRASP 
[32]. These values are comparable with those found for the 
complex between Ht-d and Pyr-Asn-Trp [33] and indicate that 
the Si' pocket is not even half filled by the Trp side-chain (see 
Fig. 3). A progressive decrease of the Si' pocket volume has 
been found in the human neutrophil collagenase [34] and hu-
man fibroblast collagenase [35]. 
The network of H-bonds between the inhibitor and the 
active site polar groups is shown in Fig. 4. Interestingly, the 
inhibitor backbone adopts a retro-binding mode, with its 
chain direction parallel to the P-sheet segment Ile108-Ser114 
of the 'upper rim' and antiparallel to the cross over and Si' 
wall forming segment Pro168-Leu170. Although the direction is 
reversed to that generally adopted by all substrate-based in-
hibitors of MMPs [36], its backbone forms H-bonds with the 
same groups of the catalytic core, except for the Trp NH that 
is H-bonded to a water molecule. A similar amino to carboxyl 
direction has been found for the extended portion of the pro-
domain in the active site of stromelysin-1 [37]. 
The inhibitor Leu side-chain adopts the g~(t,g~) conforma-
tion and one of its methyl groups forms van der Waals con-
tacts of 3.2 and 3.8 A with the Gly105 CO and one methyl 
group of He107, respectively. The furan ring is loosely involved 
in interactions with the surrounding groups. 
A structure-based sequence alignment of adamalysin II and 
TACE [12], partly reported in Table 2, was performed using 
the program MODELLER [38]. The inspection of the mod-
eled TACE active site reveals substantial similarities to those 
of adamalysin II, particularly for the elongated zinc-binding 
consensus sequence, the Met-turn, and the edge strand seg-
ment Lys106-Alam of the 'upper rim'. However, the most 
notable difference is the smaller Si' pocket of TACE, due to 
the presence of a Leu residue in place of adamalysin II Val138. 
4. Conclusion 
Because of potential toxicity associated with the extensively 
used hydroxamate inhibitors of MMPs and their preclusion to 
322 M. Cirilli et al.lFEBS Letters 418 (1997) 319-322 
bind bo th S and S' regions of the active site, other ligands are 
being exploited. The crystal structure of adamalysin II com-
plexed with a phosphonate inhibitor modeled on an endoge-
nous venom tripeptide, reveals that the terminal phosphonate 
group ligates the zinc ion in an asymmetric bidentate mode. 
The inhibitor backbone occupies the primed region, adopting 
a retro-binding mode, with the amino to carboxyl chain di-
rection opposite to that normally adopted by the substrate-
based inhibitors. This finding can suggest new ideas for the 
design of novel specific inhibitors against adamalysin II and 
related enzymes. Finally, a structural model of T A C E reveals 
a Si ' pocket smaller than that of adamalysin II. 
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